SNORD12: A Small Nucleolar RNA in Focus (G692057)

Target Name: SNORD12

NCBI ID: G692057

SNORD12

Other Name(s): small nucleolar RNA, C/D box 12 | MIR1259 | Small nucleolar RNA, C/D box 12 | HBII-99 | MIRN1259

SNORD12: A Small Nucleolar RNA in Focus

Introduction

Small nucleolar RNA (snRNA) is a class of non-coding RNAs that play a vital role in various cellular processes, including DNA replication, gene expression, and RNA processing. One of the most well-known snRNAs is SNORD12, which is a 22 -nt RNA molecule that is predominantly expressed in the nucleolus of eukaryotic cells. In this article, we will discuss the biology of SNORD12, its potential drug targets, and its role as a biomarker in various diseases.

Biogenesis and Expression

SNORD12 is a small RNA molecule that is synthesized from a single exon and contains a unique open reading frame (ORF) of 12 nucleotides. It is primarily expressed in the nucleolus, where it is involved in various cellular processes, including the preparation of RNA for protein synthesis and the modification of RNA stability. SNORD12 is predominantly synthesized from the 5' end of the ORF, and its levels in the cell can vary depending on the specific cell type and the stage of the cell cycle.

Function and Putative Functions

SNORD12 plays a critical role in regulating gene expression in the nucleolus. It is involved in the process of RNA polymerase II (RNA-II) initiation, which is the first step in the gene expression pathway. By interacting with the RNA- II complex, SNORD12 helps to recruit the necessary enzymes and substrates for initiation of the RNA-II reaction. Additionally, SNORD12 has been shown to play a role in the regulation of gene expression by affecting the levels of various RNA species, including mRNA, tRNA, and rRNA.

Drug Targets

SNORD12 has emerged as a promising drug target due to its involvement in various cellular processes and its unique expression patterns. Several studies have suggested that inhibiting the activity of SNORD12 may be a useful strategy for treating various diseases.

One potential drug target for SNORD12 is the treatment of cancer. The expression of SNORD12 is often higher in cancer cells compared to healthy cells, and it has been shown to contribute to the progression of cancer by promoting the expression of genes involved in cell growth, invasion, and metastasis. Therefore, inhibiting the activity of SNORD12 has been suggested as a potential strategy for cancer treatment.

Another potential drug target for SNORD12 is the treatment of neurodegenerative diseases. The expression of SNORD12 is often higher in neurodegenerate brain tissue compared to healthy tissue, and it has been shown to contribute to the progression of neurodegenerative diseases by promoting the expression of genes involved in neurotransmission and inflammation. Therefore, inhibiting the activity of SNORD12 has been suggested as a potential strategy for the treatment of neurodegenerative diseases.

In addition to its potential drug targets, SNORD12 has also been shown to be a potential biomarker for various diseases. The levels of SNORD12 can vary depending on the stage of the disease, and its expression has been shown to be downregulated in various diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. Therefore, measuring the levels of SNORD12 may be a useful diagnostic tool for these diseases.

Conclusion

In conclusion, SNORD12 is a small nucleolar RNA that plays a critical role in various cellular processes in eukaryotic cells. Its expression patterns and involvement in the regulation of gene expression have made it a promising drug target for the treatment of various diseases, including cancer and neurodegenerative diseases. Further research is needed to fully understand the biology of SNORD12 and its potential as a drug

Protein Name: Small Nucleolar RNA, C/D Box 12

The "SNORD12 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORD12 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets